BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Inamura K. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci 2017;18:E2195. [PMID: 29053609 DOI: 10.3390/ijms18102195] [Cited by in Crossref: 45] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Xing Z, Yuan M, Xu B, Chen L, Zhang D, Zhou Y, Huang H, Zheng X, Zhang J, Jiang J. IL1R2 promotes tumor progression via JAK2/STAT3 pathway in human clear cell renal cell carcinoma. Pathol Res Pract 2022;238:154069. [PMID: 36029680 DOI: 10.1016/j.prp.2022.154069] [Reference Citation Analysis]
2 Ju D, Liang Y, Hou G, Zheng W, Zhang G, Dun X, Wei D, Yan F, Zhang L, Lai D, Yuan J, Zheng Y, Wang F, Meng P, Wang Y, Yu W, Yuan J. FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect. Front Oncol 2022;12:928373. [DOI: 10.3389/fonc.2022.928373] [Reference Citation Analysis]
3 Li W, Cao Z, Chang P, Zhang B, Li F, Chang D, Chen S. Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial. Journal of Oncology 2022;2022:1-6. [DOI: 10.1155/2022/8100323] [Reference Citation Analysis]
4 Zeng W, Xiong G, Hua L, Hu Y, Guo X, Peng X. APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome. Sci Rep 2022;12:12406. [PMID: 35858961 DOI: 10.1038/s41598-022-16434-6] [Reference Citation Analysis]
5 Iacovelli R, Arduini D, Ciccarese C, Pierconti F, Strusi A, Piro G, Carbone C, Foschi N, Daniele G, Tortora G. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. Crit Rev Oncol Hematol 2022;176:103750. [PMID: 35728738 DOI: 10.1016/j.critrevonc.2022.103750] [Reference Citation Analysis]
6 Ganini C, Montanaro M, Scimeca M, Palmieri G, Anemona L, Concetti L, Melino G, Bove P, Amelio I, Candi E, Mauriello A. No Time to Die: How Kidney Cancer Evades Cell Death. IJMS 2022;23:6198. [DOI: 10.3390/ijms23116198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cao M, Nawalaniec K, Ajay AK, Luo Y, Moench R, Jin Y, Xiao S, Hsiao L, Waaga-gasser AM. PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner. Translational Oncology 2022;19:101377. [DOI: 10.1016/j.tranon.2022.101377] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mohamed AH, Abdullahi IM, Eraslan A, Mohamud HA, Gur M. Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia. CMAR 2022;Volume 14:1837-44. [DOI: 10.2147/cmar.s361765] [Reference Citation Analysis]
9 Liu Z, Ge L, Zhao X, Lu M, Aili A, Li Y, Zhu G, Hong P, Tian X, Wang S, Zhang H, Liu C, Ding Z, Zhang S, Ma L. Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chinese Center. Clin Med Insights Oncol 2022;16:11795549221092217. [PMID: 35465470 DOI: 10.1177/11795549221092217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Xu C, Zeng H, Fan J, Huang W, Yu X, Li S, Wang F, Long X. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09322-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ljungberg B, Albiges L, Abu-ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology 2022. [DOI: 10.1016/j.eururo.2022.03.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 27.0] [Reference Citation Analysis]
12 Gao J, Yang D, Xu H, Yang K, Ma J, Xia J, Pan X. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma. Bioengineered 2022;13:2412-29. [DOI: 10.1080/21655979.2021.2010313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li B, Zhang X, Ren Q, Gao L, Tian J. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways. Front Pharmacol 2021;12:781623. [PMID: 35082669 DOI: 10.3389/fphar.2021.781623] [Reference Citation Analysis]
14 Yang H, Zhao H, Ren Z, Yi X, Zhang Q, Yang Z, Kuang Y, Zhu Y. Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC. Acta Biochim Biophys Sin (Shanghai) 2022;54:220-31. [PMID: 35130611 DOI: 10.3724/abbs.2021023] [Reference Citation Analysis]
15 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Lin HS, Ding Q, Lichner Z, Kim SS, Saleeb R, Farag M, Di Meo A, Plant P, Kaldas M, Bjarnason GA, Yousef GM. The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance. J Clin Med 2022;11:369. [PMID: 35054064 DOI: 10.3390/jcm11020369] [Reference Citation Analysis]
17 Yan H, Bao Y, Lin Z. High Expression of JMJD4 Is a Potential Diagnostic and Prognostic Marker of Renal Cell Carcinoma. Dis Markers 2021;2021:9573540. [PMID: 34980950 DOI: 10.1155/2021/9573540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Ma S, Zhao M, Fan J, Chang M, Pan Z, Zhang Z, Xue S, Li Q, Zhang Y. Analysis of Ferroptosis-Related Gene Expression and Prognostic Factors of Renal Clear Cell Carcinoma Based on TCGA Database. Int J Gen Med 2021;14:5969-80. [PMID: 34588801 DOI: 10.2147/IJGM.S323511] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Cui Y, Zhang S, Miao C, Liang C, Chen X, Yan T, Bu H, Dong H, Li J, Li J, Wang Z, Liu B. Identification of autophagy-related long non-coding RNA prognostic and immune signature for clear cell renal cell carcinoma. Transl Androl Urol 2021;10:3317-31. [PMID: 34532256 DOI: 10.21037/tau-21-278] [Reference Citation Analysis]
20 Chang I, Ohn T, Moon D, Maeng YH, Jang BG, Yoon SP. SNU-333 Cells as an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model. Technol Cancer Res Treat 2021;20:15330338211038487. [PMID: 34490820 DOI: 10.1177/15330338211038487] [Reference Citation Analysis]
21 Jorge S, Capelo JL, LaFramboise W, Satturwar S, Korentzelos D, Bastacky S, Quiroga-Garza G, Dhir R, Wiśniewski JR, Lodeiro C, Santos HM. Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms. BMC Med 2021;19:196. [PMID: 34482820 DOI: 10.1186/s12916-021-02071-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Xie J, Sun M, Zhang D, Chen C, Lin S, Zhang G. Fibronectin enhances tumor metastasis through B7-H3 in clear cell renal cell carcinoma. FEBS Open Bio 2021;11:2977-87. [PMID: 34431237 DOI: 10.1002/2211-5463.13280] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Meng F, Zhang L, Zhang M, Ye K, Guo W, Liu Y, Yang W, Zhai Z, Wang H, Xiao J, Dai H. Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma. Cancer Cell Int 2021;21:332. [PMID: 34193180 DOI: 10.1186/s12935-021-02039-y] [Reference Citation Analysis]
24 Panunzio A, Tafuri A, Princiotta A, Gentile I, Mazzucato G, Trabacchin N, Antonelli A, Cerruto MA. Omics in urology: An overview on concepts, current status and future perspectives. Urologia 2021;:3915603211022960. [PMID: 34169788 DOI: 10.1177/03915603211022960] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Choi JW, Hu R, Zhao Y, Purkayastha S, Wu J, McGirr AJ, Stavropoulos SW, Silva AC, Soulen MC, Palmer MB, Zhang PJL, Zhu C, Ahn SH, Bai HX. Preoperative prediction of the stage, size, grade, and necrosis score in clear cell renal cell carcinoma using MRI-based radiomics. Abdom Radiol (NY) 2021;46:2656-64. [PMID: 33386910 DOI: 10.1007/s00261-020-02876-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Barthélémy P, Rioux-Leclercq N, Thibault C, Saldana C, Borchiellini D, Chevreau C, Desmoulins I, Gobert A, Hilgers W, Khalil A, Lemoine N, Schlürmann-Constans F, Négrier S. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. Cancer Treat Rev 2021;97:102191. [PMID: 34015728 DOI: 10.1016/j.ctrv.2021.102191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, Rathmell WK, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC. Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer 2021;19:167-75. [DOI: 10.1016/j.clgc.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Möller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, Büscheck F, Höppner W, Matthies C, Doh O, Krech T, Marx AH, Zecha H, Rink M, Steurer S, Clauditz TS. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. Int Urol Nephrol 2021. [PMID: 33797012 DOI: 10.1007/s11255-021-02841-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Guglielmo P, Gasparro D, Scarlattei M, Baldari G, Bola S, Migliari S, Sammartano A, Maestroni U, Ruffini L. [68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2021;48:3337-9. [PMID: 33754194 DOI: 10.1007/s00259-021-05250-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Junejo NN, Alkhateeb SS, Alrumayyan MF, Alkhatib KY, Alzahrani HM, Alotaibi MF, Alothman KI, Al-Hussain TO, Altaweel WM. Trends in the surgical management of renal cell carcinoma in a contemporary tertiary care setting. Urol Ann 2021;13:111-8. [PMID: 34194135 DOI: 10.4103/UA.UA_151_20] [Reference Citation Analysis]
31 Nicolau C, Antunes N, Paño B, Sebastia C. Imaging Characterization of Renal Masses. Medicina (Kaunas) 2021;57:51. [PMID: 33435540 DOI: 10.3390/medicina57010051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Santoni M, Piva F, Porta C, Bracarda S, Heng DY, Matrana MR, Grande E, Mollica V, Aurilio G, Rizzo M, Giulietti M, Montironi R, Massari F. Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clin Genitourin Cancer 2021;19:e84-91. [PMID: 33262083 DOI: 10.1016/j.clgc.2020.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kampantais S, Kounatidis I, Kotoula V, Vakalopoulos I, Gkagkalidis K, Dimitriadis G. Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma. Int J Biol Markers 2020;35:80-6. [PMID: 33118406 DOI: 10.1177/1724600820960478] [Reference Citation Analysis]
34 Moldovanu CG, Petresc B, Lebovici A, Tamas-Szora A, Suciu M, Crisan N, Medan P, Buruian MM. Differentiation of Clear Cell Renal Cell Carcinoma from other Renal Cell Carcinoma Subtypes and Benign Oncocytoma Using Quantitative MDCT Enhancement Parameters. Medicina (Kaunas) 2020;56:E569. [PMID: 33126571 DOI: 10.3390/medicina56110569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Liu S, Wang F, Tan W, Zhang L, Dai F, Wang Y, Fan Y, Yuan M, Yang D, Zheng Y, Deng Z, Liu Y, Cheng Y. CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC). Cancer Cell Int 2020;20:519. [PMID: 33117084 DOI: 10.1186/s12935-020-01603-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
36 Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, Messina C, Rediti M, Russo A, Bazan V, Iovanna JL. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology 2020;9:1832348. [PMID: 33178494 DOI: 10.1080/2162402X.2020.1832348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
37 Shan L, Liu W, Zhan Y. Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma. Front Oncol 2020;10:516552. [PMID: 33072561 DOI: 10.3389/fonc.2020.516552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
38 Osterman CK, Deal AM, Milowsky MI, Bjurlin MA, Rose TL. Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer 2020;4:131-7. [PMID: 33195888 DOI: 10.3233/KCA-200089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Cao W, Kang R, Xiang Y, Hong J. Human Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma: Biological Functions and Clinical Values. Onco Targets Ther 2020;13:7877-85. [PMID: 32821127 DOI: 10.2147/OTT.S259534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Davaro F, Davaro E, Qureshi A, Lombardo L. A Case of Heterotopic Ossification in Papillary Renal Cell Carcinoma Type 2. Case Rep Urol 2020;2020:5126802. [PMID: 32855835 DOI: 10.1155/2020/5126802] [Reference Citation Analysis]
41 Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Nakayama Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A, Tamada S. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. Int J Urol 2020;27:952-9. [PMID: 32789967 DOI: 10.1111/iju.14329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
42 Ingrosso D, Perna AF. DNA Methylation Dysfunction in Chronic Kidney Disease. Genes (Basel) 2020;11:E811. [PMID: 32708735 DOI: 10.3390/genes11070811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Zhu H, Zhao S, Zuo C, Ren F. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation. AJR Am J Roentgenol 2020;215:645-51. [PMID: 32755159 DOI: 10.2214/AJR.19.22467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Song C, Kong Y, Huang L, Luo H, Zhu X. Big data-driven precision medicine: Starting the custom-made era of iatrology. Biomed Pharmacother 2020;129:110445. [PMID: 32593132 DOI: 10.1016/j.biopha.2020.110445] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
45 Lai J, Xin J, Fu C, Zhang W. CircHIPK3 promotes proliferation and metastasis and inhibits apoptosis of renal cancer cells by inhibiting MiR-485-3p. Cancer Cell Int 2020;20:248. [PMID: 32550826 DOI: 10.1186/s12935-020-01319-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
46 Thouvenin J, Barthélémy P, Ladoire S. Les cancers du rein non à cellules claires : caractéristiques clinico-biologiques et prise en charge thérapeutique hors chirurgie. Bulletin du Cancer 2020;107:S56-65. [DOI: 10.1016/s0007-4551(20)30279-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH. Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes. Cancers (Basel) 2020;12:E602. [PMID: 32150988 DOI: 10.3390/cancers12030602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
48 Miranda-Gonçalves V, Lameirinhas A, Henrique R, Baltazar F, Jerónimo C. The metabolic landscape of urological cancers: New therapeutic perspectives. Cancer Lett 2020;477:76-87. [PMID: 32142920 DOI: 10.1016/j.canlet.2020.02.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
49 Luo J, Luo X, Liu X, Fang Z, Xu J, Li L. DUSP9 Suppresses Proliferation and Migration of Clear Cell Renal Cell Carcinoma via the mTOR Pathway. Onco Targets Ther 2020;13:1321-30. [PMID: 32103999 DOI: 10.2147/OTT.S239407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
50 Tutunea-Fatan E, Lee JC, Denker BM, Gunaratnam L. Heterotrimeric Gα12/13 proteins in kidney injury and disease. Am J Physiol Renal Physiol 2020;318:F660-72. [PMID: 31984793 DOI: 10.1152/ajprenal.00453.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Życzkowski M, Kaletka Z, Rajwa P, Rempega G, Stelmach P, Bogacki R, Łach-Wojnarowicz O, Paradysz E. Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy. Int Urol Nephrol 2020;52:885-91. [PMID: 31953718 DOI: 10.1007/s11255-020-02379-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
52 Osterman CK, Rose TL. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma. Kidney Cancer 2020;4:15-27. [PMID: 34435168 DOI: 10.3233/kca-190078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Kim H, Komiyama T, Nitta M, Kawamura Y, Hasegawa M, Shoji S, Orihashi Y, Inomoto C, Kajiwara H, Nakamura N, Kobayashi H, Miyajima A. D-loop Mutations in Renal Cell Carcinoma Improve Predictive Accuracy for Cancer-Related Death by Integrating with Mutations in the NADH Dehydrogenase Subunit 1 Gene. Genes (Basel) 2019;10:E998. [PMID: 31810328 DOI: 10.3390/genes10120998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chen YH, Chen SH, Hou J, Ke ZB, Wu YP, Lin TT, Wei Y, Xue XY, Zheng QS, Huang JB, Xu N. Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis. Aging (Albany NY) 2019;11:9478-91. [PMID: 31672930 DOI: 10.18632/aging.102397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
55 Sun T, Hutchinson L, Zhou AG, Liu Q, Cosar EF, St. Cyr M, Ninteau N, Dresser K, Cheng L, Jiang Z, Cornejo KM. The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. Int J Surg Pathol 2020;28:259-64. [DOI: 10.1177/1066896919883016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Mantia CM, McDermott DF. Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. Cancer 2019;125:4148-57. [PMID: 31532565 DOI: 10.1002/cncr.32361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
57 Chen W, Zhuang J, Wang PP, Jiang J, Lin C, Zeng P, Liang Y, Zhang X, Dai Y, Diao H. DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups. Cancer Cell Int 2019;19:185. [PMID: 31346320 DOI: 10.1186/s12935-019-0900-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
58 Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Sci 2019;110:1897-908. [PMID: 31006167 DOI: 10.1111/cas.14026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
59 Antonelli A, Veccia A, Autorino R. Metachronous renal cell carcinoma: an unbeatable leviathan? Ann Transl Med 2019;7:169. [PMID: 31168450 DOI: 10.21037/atm.2019.03.43] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Życzkowski M, Rajwa P, Burzyński B, Gaździk M, Florczyk I, Slabon-Turska M, Paradysz A. Neutrophil-to-mean platelet volume ratio as a new predictor for overall and cancer-specific survival in patients with localized clear cell renal cell carcinoma. Arch Med Sci 2020;16:1072-7. [PMID: 32863996 DOI: 10.5114/aoms.2019.83822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 2019;75:799-810. [PMID: 30803729 DOI: 10.1016/j.eururo.2019.02.011] [Cited by in Crossref: 383] [Cited by in F6Publishing: 581] [Article Influence: 127.7] [Reference Citation Analysis]
62 Quddus MB, Pratt N, Nabi G. Chromosomal aberrations in renal cell carcinoma: An overview with implications for clinical practice. Urol Ann 2019;11:6-14. [PMID: 30787564 DOI: 10.4103/UA.UA_32_18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
63 Sun M, Guo S, Yao J, Xiao Y, Sun R, Ma W, Dong Z. MicroRNA‐125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells. J Cell Biochem 2019;120:1894-902. [DOI: 10.1002/jcb.27503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
64 Hui K, Yue Y, Wu S, Gu Y, Guan B, Wang X, Hsieh JT, Chang LS, He D, Wu K. The expression and function of RASAL2 in renal cell carcinoma angiogenesis. Cell Death Dis 2018;9:881. [PMID: 30158581 DOI: 10.1038/s41419-018-0898-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
65 Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review. Int J Mol Sci 2018;19:E2529. [PMID: 30149673 DOI: 10.3390/ijms19092529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
66 Cazorla-Vázquez S, Engel FB. Adhesion GPCRs in Kidney Development and Disease. Front Cell Dev Biol 2018;6:9. [PMID: 29468160 DOI: 10.3389/fcell.2018.00009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]